Human mesenchymal stem cells from peripheral blood

• US 6,261,549 B1
• Filed: 07/01/1998
• Issued: 07/17/2001
• Est. Priority Date: 07/03/1997
• Status: Expired due to Term

• Current Assignee: Mesoblast International Srl
• Original Assignee: Osiris Therapeutics Incorporated (Smith & Nephew PLC)
• Inventors: Minguell, José J., Fernández, Mireya
• Primary Examiner(s): Clark, Deborah J. R.
• Assistant Examiner(s): Kerr, Janet M
• Application Number:
  US09/108,838
• Time in Patent Office: 1,112 Days
• Field of Search: 424/85.1, 424/85.2, 424/93.7, 514/2, 514/12, 530/350, 530/351, 930/140, 930/145
• US Class Current: 424/85.1
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: C12N 5/0665 Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood
• CPC Class Codes: Y10S 930/14 Lymphokine; related peptides

Abstract

Disclosed is a method for recovering peripheral blood containing a population of cells enhanced in human mesenchymal stem cells from an individual by (i) administering to said individual at least one growth factor and, thereafter, (ii) recovering peripheral blood from said individual. The growth factors preferably include G-CSF, GM-CSF and combinations thereof. Any of the known human growth factors or combinations thereof are suitable. Also disclosed is a method for recovering an isolated, culture-expanded population of human mesenchymal stem cells from the mesenchymal stem cell-enriched peripheral blood of an individual. Also disclosed is a method for preserving ex vivo an isolated, culture-expanded population of human mesenchymal stem cells from the mesenchymal stem cell-enriched peripheral blood. Also disclosed is a method for treating an individual with an isolated, culture-expanded population of human mesenchymal stem cells.

Claims

1. A process for obtaining human mesenchymal stem cells from an individual, comprising:

administering to the individual an effective amount of a growth factor that increases the amount of mesenchymal stem cells in peripheral blood, said growth factor being selected from the group consisting of G-CSF and GM-CSF;

recovering from said individual mesenchymal stem cell enriched peripheral blood; and

recovering the mesenchymal stem cells from the mesenchymal stem cell enriched peripheral blood, wherein the human mesenchymal stem cells are SH2+, SH3+, and/or SH4+.

2. The process of claim 1, wherein the mesenchymal stem cells are further CD14−

and CD34−

.